In an effort to contain healthcare costs, governments around the world are imposing increasingly stricter pricing and reimbursement conditions in particular one “me-too” medicines. We study the consequences that this may have on pharmaceutical innovation in the context of a dynamic model of drug development. Our simulations show that the negative effects of price regulation on drug development are economically significant.

 Go to newsletter